These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

258 related items for PubMed ID: 16507585

  • 1. Fontolizumab, a humanised anti-interferon gamma antibody, demonstrates safety and clinical activity in patients with moderate to severe Crohn's disease.
    Hommes DW, Mikhajlova TL, Stoinov S, Stimac D, Vucelic B, Lonovics J, Zákuciová M, D'Haens G, Van Assche G, Ba S, Lee S, Pearce T.
    Gut; 2006 Aug; 55(8):1131-7. PubMed ID: 16507585
    [Abstract] [Full Text] [Related]

  • 2. A dose escalating, placebo controlled, double blind, single dose and multidose, safety and tolerability study of fontolizumab, a humanised anti-interferon gamma antibody, in patients with moderate to severe Crohn's disease.
    Reinisch W, Hommes DW, Van Assche G, Colombel JF, Gendre JP, Oldenburg B, Teml A, Geboes K, Ding H, Zhang L, Tang M, Cheng M, van Deventer SJ, Rutgeerts P, Pearce T.
    Gut; 2006 Aug; 55(8):1138-44. PubMed ID: 16492717
    [Abstract] [Full Text] [Related]

  • 3. A randomised placebo-controlled multicentre trial of intravenous semapimod HCl for moderate to severe Crohn's disease.
    Dotan I, Rachmilewitz D, Schreiber S, Eliakim R, van der Woude CJ, Kornbluth A, Buchman AL, Bar-Meir S, Bokemeyer B, Goldin E, Maaser C, Mahadevan U, Seidler U, Hoffman JC, Homoky D, Plasse T, Powers B, Rutgeerts P, Hommes D, Semapimod-CD04/CD05 Investigators.
    Gut; 2010 Jun; 59(6):760-6. PubMed ID: 20551461
    [Abstract] [Full Text] [Related]

  • 4. Natalizumab for the treatment of active Crohn's disease: results of the ENCORE Trial.
    Targan SR, Feagan BG, Fedorak RN, Lashner BA, Panaccione R, Present DH, Spehlmann ME, Rutgeerts PJ, Tulassay Z, Volfova M, Wolf DC, Hernandez C, Bornstein J, Sandborn WJ, International Efficacy of Natalizumab in Crohn's Disease Response and Remission (ENCORE) Trial Group.
    Gastroenterology; 2007 May; 132(5):1672-83. PubMed ID: 17484865
    [Abstract] [Full Text] [Related]

  • 5. Anti-interleukin-12 antibody for active Crohn's disease.
    Mannon PJ, Fuss IJ, Mayer L, Elson CO, Sandborn WJ, Present D, Dolin B, Goodman N, Groden C, Hornung RL, Quezado M, Yang Z, Neurath MF, Salfeld J, Veldman GM, Schwertschlag U, Strober W, Anti-IL-12 Crohn's Disease Study Group.
    N Engl J Med; 2004 Nov 11; 351(20):2069-79. PubMed ID: 15537905
    [Abstract] [Full Text] [Related]

  • 6. Fontolizumab in moderate to severe Crohn's disease: a phase 2, randomized, double-blind, placebo-controlled, multiple-dose study.
    Reinisch W, de Villiers W, Bene L, Simon L, Rácz I, Katz S, Altorjay I, Feagan B, Riff D, Bernstein CN, Hommes D, Rutgeerts P, Cortot A, Gaspari M, Cheng M, Pearce T, Sands BE.
    Inflamm Bowel Dis; 2010 Feb 11; 16(2):233-42. PubMed ID: 19637334
    [Abstract] [Full Text] [Related]

  • 7. Natalizumab for active Crohn's disease.
    Ghosh S, Goldin E, Gordon FH, Malchow HA, Rask-Madsen J, Rutgeerts P, Vyhnálek P, Zádorová Z, Palmer T, Donoghue S, Natalizumab Pan-European Study Group.
    N Engl J Med; 2003 Jan 02; 348(1):24-32. PubMed ID: 12510039
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Defining the optimal response criteria for the Crohn's disease activity index for induction studies in patients with mildly to moderately active Crohn's disease.
    Thia KT, Sandborn WJ, Lewis JD, Loftus EV, Feagan BG, Steinhart AH, Hanauer SB, Persson T, Sands BE.
    Am J Gastroenterol; 2008 Dec 02; 103(12):3123-31. PubMed ID: 18786111
    [Abstract] [Full Text] [Related]

  • 11. CDP571, a humanised monoclonal antibody to tumour necrosis factor alpha, for moderate to severe Crohn's disease: a randomised, double blind, placebo controlled trial.
    Sandborn WJ, Feagan BG, Radford-Smith G, Kovacs A, Enns R, Innes A, Patel J.
    Gut; 2004 Oct 02; 53(10):1485-93. PubMed ID: 15361500
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Budesonide CIR capsules (once or twice daily divided-dose) in active Crohn's disease: a randomized placebo-controlled study in the United States.
    Tremaine WJ, Hanauer SB, Katz S, Winston BD, Levine JG, Persson T, Persson A, Budesonide CIR United States Study Group.
    Am J Gastroenterol; 2002 Jul 02; 97(7):1748-54. PubMed ID: 12135030
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Budesonide as maintenance treatment in Crohn's disease: a placebo-controlled trial.
    Hanauer S, Sandborn WJ, Persson A, Persson T.
    Aliment Pharmacol Ther; 2005 Feb 15; 21(4):363-71. PubMed ID: 15709986
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial.
    Colombel JF, Sandborn WJ, Rutgeerts P, Enns R, Hanauer SB, Panaccione R, Schreiber S, Byczkowski D, Li J, Kent JD, Pollack PF.
    Gastroenterology; 2007 Jan 15; 132(1):52-65. PubMed ID: 17241859
    [Abstract] [Full Text] [Related]

  • 20. Efficacy of a pelargonium sidoides preparation in patients with the common cold: a randomized, double blind, placebo-controlled clinical trial.
    Lizogub VG, Riley DS, Heger M.
    Explore (NY); 2007 Jan 15; 3(6):573-84. PubMed ID: 18005909
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.